Pharmicell (005690) - Total Liabilities

Latest as of September 2025: ₩19.60 Billion KRW ≈ $13.28 Million USD

Based on the latest financial reports, Pharmicell (005690) has total liabilities worth ₩19.60 Billion KRW (≈ $13.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Pharmicell - Total Liabilities Trend (2010–2024)

This chart illustrates how Pharmicell's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Pharmicell's working capital to evaluate short-term liquidity relative to the company's equity base.

Pharmicell Competitors by Total Liabilities

The table below lists competitors of Pharmicell ranked by their total liabilities.

Company	Country	Total Liabilities
Cheng Uei Precision Industry Co Ltd TW:2392	Taiwan	NT$95.67 Billion
Sayona Mining Ltd AU:SYA	Australia	AU$177.27 Million
Mutares SE & Co. KGaA XETRA:MUX	Germany	€4.33 Billion
Ta Ann Holdings Bhd KLSE:5012	Malaysia	RM691.13 Million
Qingdao Copton Technology Co Ltd SHG:603798	China	CN¥169.56 Million
Zhejiang Jihua Group Co Ltd SHG:603980	China	CN¥590.92 Million
Shenzhen King Brother Electronics Technology Co.Ltd. SHE:301041	China	CN¥259.98 Million
Qurient Co. Ltd KQ:115180	Korea	₩6.81 Billion

Liability Composition Analysis (2010–2024)

This chart breaks down Pharmicell's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pharmicell market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmicell's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmicell (2010–2024)

The table below shows the annual total liabilities of Pharmicell from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩12.83 Billion ≈ $8.69 Million	+5.80%
2023-12-31	₩12.12 Billion ≈ $8.21 Million	-63.25%
2022-12-31	₩32.98 Billion ≈ $22.35 Million	+8.28%
2021-12-31	₩30.46 Billion ≈ $20.64 Million	+141.01%
2020-12-31	₩12.64 Billion ≈ $8.57 Million	+7.60%
2019-12-31	₩11.75 Billion ≈ $7.96 Million	+1.03%
2018-12-31	₩11.63 Billion ≈ $7.88 Million	+49.86%
2017-12-31	₩7.76 Billion ≈ $5.26 Million	+5.44%
2016-12-31	₩7.36 Billion ≈ $4.99 Million	-56.58%
2013-12-31	₩16.95 Billion ≈ $11.49 Million	-51.36%
2012-12-31	₩34.84 Billion ≈ $23.61 Million	+90.07%
2011-12-31	₩18.33 Billion ≈ $12.42 Million	-7.59%
2010-12-31	₩19.84 Billion ≈ $13.45 Million	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$579.46 Million

₩855.06 Billion KRW

Market Cap Rank

#11637 Global

#324 in Korea

Share Price

₩14250.00

Change (1 day)

-3.72%

52-Week Range

₩10460.00 - ₩20250.00

All Time High

₩25150.00